Using thousands of AI agents to uncover new leads in biological data

The thread barely treated the agent swarm as a biological breakthrough. Most readers fixated on the gap between producing an attractive mechanistic story and proving that it changes outcomes for patients. Clinical research already has no shortage of plausible targets, they argued; the expensive, failure-prone work is validating causality, surviving human trials, and making any resulting treatment affordable. Several readers found the showcased Alzheimer’s angle especially unconvincing because it connected an already disease-linked gene to a broad, unsurprising neurodegeneration mechanism without establishing why its proposed cholesterol link deserves priority over countless alternatives. A smaller group saw a real role for AI, but not as a substitute for experimental science. Better in-silico and animal models could filter false leads before costly trials, while AI could help researchers navigate trial design and regulatory complexity. Others defended ambitious scientific automation on principle: if it accelerates cures or fundamental discovery, protecting the satisfaction scientists get from doing the work is a poor objection. Yet even that camp did not offer evidence that this multi-agent exercise has cleared the crucial validation bar. The sharpest skepticism was aimed at presentation. Commenters read the emphasis on experts preferring distributed-agent reports as a benchmark for polished summaries, not proof that the system can discover medically actionable biology. To them, the release felt like valuation-driven AI hype wrapped around hypotheses that competent researchers generate routinely.